In response to reports claiming companies are not providing medication on credit as a result of the unfavourable for our country developments in the economy, the Cyprus Association of Research and Development Pharmaceutical Companies (KEFEA) assures consumers that the...
Mr Daan Gijbels, of Dutch descent and Area General Manager for GlaxoSmithKline (Cyprus), is the new president of the Cyprus Association of Research & Development Pharmaceutical Companies (KEFEA). He took over from Jacqueline Anastassiades, General Manager of Merck...
The Cyprus Association of Research and Development Pharmaceutical Companies (KEFEA), met with Presidential Candidate Giorgos Lillikas, within the framework of its meetings with the presidential candidates. “We had a very substantive dialogue with Mr. Lillikas...
The Cyprus Association of Research and Development Pharmaceutical Companies (KEFEA) expresses the belief that the change in the pricing policy for medicines, as has been approved by Cabinet, ensures, under the circumstances, the continued availability of the majority...
The foundation for creating a network for research and innovation in Cyprus has been set by the meeting for the European Innovative Medicines Initiative (IMI) programme, held on July 3, at the Cyprus Institute of Neurology and Genetics. With a budget of €2 billion,...
The Cyprus Association of Cyprus Association of Research and Development Pharmaceutical Companies (KEFEA) commends the decision of the Cabinet to approve the implementation proposal of a National Health System (GESY) in Cyprus, which was presented by the Ministry of...
Please download the Agenda and Invitation. IMI Info Day July 3rd invitation The Minister of Health Dr Stavros Malas, will address the event. The info meeting is specially addressed to interested parties from the pharmaceutical industry, academia, small and...
€2 bln for research programmes An informative meeting, which aims to promote Cypriot participation in the present and future calls of the European Innovative Medicines Initiative (IMI) project, the submission of research proposals and the creation of an IMI network in...
The recent findings made public from the comparative study prepared by the Pharmaceutical Services of the Ministry of Health for the pricing of drugs in Cyprus have caused great concern. The Cyprus Association of Pharmaceutical Research and Development Companies...
The Cyprus Association of Research and Development Pharmaceutical Companies (KEFEA) has been following with great concern the sudden change in policy on behalf of the Ministry of Health, in relation to the application of contracts for the purchase of medications....
Key Messages: The current country basked correctly reflects the socio-economic level of Cyprus The economic situation of Greece is not comparable with Cyprus A better implementation of the current P&R mechanism can improve affordability of medicines for...
In a separate meeting, Minister of Finance and EFPIA General Director stressed the importance of implementing a universal health system in Cyprus that will enhance innovation and research and improve healthcare. The industry expressed its commitment to contribute to...
